Clinical trials: Fatty Liver Disease
Non-alcoholic Fatty Liver Disease
Validity of Laboratory Biomarkers in Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) and It's Consequences
The validity of laboratory biomarkers in the diagnosis of NAFLD is still not established, and adherence to a healthy dietary lifestyle for those patients in our community is not well studied.
- Trial name
- NCT06908122
- Testing
- laboratory biomarkers in the diagnosis of NAFLD disease
- Volunteers
- 100 people
- Sponsor
- Assiut University
Nonalcoholic Fatty Liver Disease
Gastric Bypass Stent Small-Sample-Size Study For Nonalcoholic Fatty Liver Disease
Evaluate the preliminary effectiveness and safety of the Gastric Bypass Stent System in treating nonalcoholic fatty liver disease.
- Trial name
- NCT05495139
- Testing
- Gastric Bypass Stent System in Treatment of Patients with Nonalcoholic Fatty Liver Disease
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hangzhou Tangji Medical Technology Co., Ltd.
PCOS, NAFLD
Androgens and NAFLD Longitudinal Cohort Study
The researchers want to learn how androgens, a type of sex hormone, might affect nonalcoholic fatty liver (NAFLD) in young women over time.
- Conditions
- PCOS, NAFLD, NASH
- Trial name
- NCT06124261
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of California, San Francisco
Nonalcoholic Steatohepatitis, Fibrosis
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis
- Trial name
- NASH (NCT05011305)
- Testing
- Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg
- Where
- 129 sites in United States, Argentina and 2 more
- Volunteers
- 189 people
- Sponsor
- Zydus Therapeutics Inc.
Obesity, Morbid, Bariatric Surgery Candidate
Investigation of Microbiome-based Prognostical Biomarkers in Patients With Morbid Obesity and Bariatric Surgery
Morbid obesity leads to non-alcoholic fatty liver disease (NAFLD), and not all NAFLD cases benefit from weight loss e.g. after bariatric surgery.
- Conditions
- Obesity, Morbid, Bariatric Surgery Candidate, NAFLD, Microbiome
- Trial name
- NCT03391401
- Testing
- Bariatric surgery
- Where
- 2 sites in Germany
- Volunteers
- 204 people
- Sponsor
- St. Franziskus Hospital
Liver Fibrosis, Liver Steatosis
The Sonic Incytes Liver Incyte System, Assessment of Liver Fibrosis and Steatosis
Evaluate the feasibility of the Liver Incyte system for liver elasticity measurement in healthy volunteers and patients with liver fibrosis.
- Trial name
- NCT03957070
- Testing
- Liver Incyte
- Where
- 2 sites in United States, Canada
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Sonic Incytes
Diabetes type2, NASH - Nonalcoholic Steatohepatitis
NASH and Type 2 Diabetes: Role of the Receptor Activator of Nuclear Factor-κB (RANK) and Its Ligand (RANKL)
Non-alcoholic fatty liver diseases (NAFLD) include several entities ranging from simple steatosis to hepatic fibrosis or cirrhosis.
- Conditions
- Diabetes type2, NASH - Nonalcoholic Steatohepatitis, NAFLD
- Trial name
- NADRANK-1 (NCT03968354)
- Testing
- "Collection of additional blood tubes; Biobanking (plasma, liver tissue).
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non-alcoholic Fatty Liver Disease, NAFLD
Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease
There is a significant association between autonomic dysfunction and symptoms experienced by NAFLD patients mediated by increased systemic inflammation and insulin resistance, resulting in deteriorating quality of life of…
- Conditions
- Non-alcoholic Fatty Liver Disease, NAFLD, Fatty Liver, Nonalcoholic, Nonalcoholic Fatty Liver Disease
- Trial name
- AD-NAFLD (NCT02132780)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Virginia Commonwealth University
Metabolic-associated Fatty Liver Disease, Type 2 Diabetes
Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D
The co-administration of SGLT2 inhibitor and GLP-1 receptor agonist would be safe and effective on glycemic control in subjects with type 2 diabetes mellitus and MAFLD better than empagliflozin or dulaglutide alone.
- Trial name
- NCT05140694
- Testing
- Empagliflozin, Dulaglutide, Empagliflozin and Dulaglutide
- Volunteers
- 135 people
- Sponsor
- Seoul National University Bundang Hospital
Liver Disease
Quantitative Diagnosis of Fatty Liver by Dual Energy CT Technique
This study is proposed to explore the correlation between fatty content of fatty liver and the difference of CT attenuation value in men using dual-energy CT, and to set up a threshold for diagnosis of fatty liver.
- Trial name
- NCT00172705
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
NASH - Nonalcoholic Steatohepatitis
Study to Evaluate MET642 in Patients With NASH
A randomized, double-blind, placebo-controlled study to evaluate MET642 in NASH patients.
- Trial name
- NCT04773964
- Testing
- MET642
- Where
- United States
- Volunteers
- 215 people
- Sponsor
- Metacrine, Inc.
Fatty Liver, Nonalcoholic Steatohepatitis
Treatment of Nonalcoholic Steatohepatitis With Pioglitazone
This study will evaluate the effectiveness of pioglitazone, a new diabetes medicine, on decreasing insulin resistance and improving liver disease in patients with nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT00013598
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)
A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients
This study is a double-blind randomized, placebo-controlled, parallel-group, 12 week study performed in up to 5 centres in Sweden to assess the effect of Omega-3 carboxylic acids and dapagliflozin on liver fat in patients with…
- Trial name
- EFFECTII (NCT02279407)
- Testing
- Omega-3 carboxylic acids, Dapagliflozin
- Where
- 5 sites in Sweden
- Volunteers
- 223 people
- Sponsor
- AstraZeneca
Metabolic Dysfunction-Associated Steatotic Liver Disease
Impact of Live Streaming Exercise on Liver Health in MASLD Pregnant Women
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) is a clinical and pathological syndrome characterized primarily by excessive intracellular fat accumulation in the liver, excluding alcohol-related and other…
- Trial name
- NCT06682663
- Testing
- Live Streaming Exercise
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Peking University
NASH - Nonalcoholic Steatohepatitis
Bariatric Surgery vs. Lifestyle Modification for NASH
Randomized Controlled Trial comparing the effects of Bariatric Surgery vs. Lifestyle modification on NASH resolution.
- Trial name
- BeLEANeR (NCT04298736)
- Testing
- Bariatric Surgery, Lifestyle modification
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Overweight and Obesity, NAFLD
Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects
The primary objective of this study is to evaluate the safety, tolerability and compare the pharmacokinetic parameters of ASC41, a THR beta agonist tables in overweight and obese subjects who have elevated LDL-C .
- Conditions
- Overweight and Obesity, NAFLD, Hyperlipidemia
- Trial name
- NCT04686994
- Testing
- ASC 41
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Gannex Pharma Co., Ltd.
Nonalcoholic Steatohepatitis
Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis
The purpose of this study is to investigate whether 48 weeks treatment with once-daily injections of liraglutide improves liver disease (liver fat, inflammation and scarring) and related metabolic parameters in overweight…
- Trial name
- LEAN (NCT01237119)
- Testing
- Liraglutide
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- University of Birmingham
Type 2 Diabetes, Prediabetes
Seum Bile Acid Profile in Type 2 Diabetes and Association Between Bile Cid Profile and Adipokine or Oxidative Stress
"The goal of this work is to critically test the hypothesis that there exists a different profile of bile acids (BAs) in patient with type 2 diabetes mellitus (T2DM) compared with normal controls.
- Conditions
- Type 2 Diabetes, Prediabetes, Non-alcoholic Fatty Liver Disease, Metabolic Syndrome
- Trial name
- NCT02650830
- Where
- South Korea
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Non-Alcoholic Fatty Liver Disease, Metabolic Encephalopathy
Prognostic Significance of Fatty Liver Disease in Bariatric Patients
Prospective non-randomized intervention case control study on patients with a BMI > 35. The intervention group/cases (n=600) is comprised of bariatric patients who undergo bariatric surgery and the control group (n=600) of age…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Metabolic Encephalopathy, Obesity, Morbid, Non-alcoholic Steatohepatitis
- Trial name
- PROMETHEUS (NCT03535142)
- Testing
- Bariatric surgery
- Where
- Denmark
- Volunteers
- 1,200 people
- Sponsor
- Esbjerg Hospital - University Hospital of Southern Denmark
Diabetes Mellitus, Type 2
Effect of Low-glycemic Index Meals Intake on DM2 Women Under Metformin Therapy
To compare the effect of low-glycemic index versus control lunches and dinners intake on indicators of satiety, metabolic parameters and liver steatosis degree on women with type 2 diabetes under metformin therapy.
- Trial name
- LGIM (NCT03165877)
- Testing
- Low-glycemic index, Control
- Volunteers
- 13 people
- Sponsor
- Universidad de Valparaiso